No current GLP-1 label lists people with HIV as an approved use, so prescribing one for it would be off-label. Randomized trial, NIH funded (Semaglutide): In HIV-associated lipohypertrophy, abdominal visceral fat fell 30.6% over 32 weeks against placebo. The authors want larger trials to check serious side effects. ClinicalTrials.gov lists 12 trials of these medicines on it: 3 with posted results and 4 recruiting now.
Read from the registry and PubMed every day. The newest update here is Oct 27, 2026.
Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.
Semaglutide · 108 people · Better than the comparison · Placebo-controlled randomized trial
In HIV-associated lipohypertrophy, abdominal visceral fat fell 30.6% over 32 weeks against placebo. The authors want larger trials to check serious side effects.
A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.
| Medicine | Trials | Posted results | Recruiting |
|---|---|---|---|
| Semaglutide | 7 | 2 | 4 |
| Liraglutide | 2 | 0 | 0 |
| Tirzepatide | 2 | 0 | 0 |
| Exenatide | 1 | 1 | 0 |
Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.
| Trial | Medicine | Phase | People | Result |
|---|---|---|---|---|
| NCT01791465Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults | Exenatide | Phase 4 | 6 | On ClinicalTrials.gov |
| NCT04019197Effects of Semaglutide in HIV-Associated Lipohypertrophy | Semaglutide | Phase 2 | 108 | Effects of Semaglutide on Quantity of Ectopic Fat (Total Pericardial Fat) at Week 32 Compared to Baseline (mL), 32 weeks. Semaglutide: -1.85; Placebo: 0.00. |
| NCT04216589Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) | Semaglutide | Phase 2 | 51 | On ClinicalTrials.gov |
The registry page names each site and who can enroll. Ask your clinician before joining one.
| Trial | Medicine | Phase | Expected to finish |
|---|---|---|---|
| GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV | Semaglutide | Phase 2 | Jan 31, 2030 |
| Incretin Microdosing for Cardiometabolic Health in People With HIV | Semaglutide | Phase 2 | Jun 30, 2029 |
| Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide | Semaglutide | Phase 2 | Jun 30, 2027 |
| Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV | Semaglutide | Not phased | Jul 2027 |
Randomized trial · Open Forum Infect Dis · Oct 5, 2026 · Adekunle RO et al.
Randomized trial · Nat Commun · May 19, 2026 · Corley MJ et al. · cited by 7
Randomized trial · Clin Infect Dis · May 1, 2026 · Atieh O et al. · cited by 6
Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.
Randomized trial, NIH funded (Semaglutide, 108 people): In HIV-associated lipohypertrophy, abdominal visceral fat fell 30.6% over 32 weeks against placebo. The authors want larger trials to check serious side effects.
Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.
Semaglutide, with 7 registered trials on it, then Liraglutide with 2. More trials do not mean better results: read what each posted.
4 trials are recruiting on ClinicalTrials.gov now, listed below with their registry pages, which name each site and who can enroll.